cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
13 own
13 watching
Current Price
$3.47
$0.01
(0.29%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
558.27M
52-Week High
52-Week High
6.89000
52-Week Low
52-Week Low
2.23000
Average Volume
Average Volume
1.98M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization558.27M
icon52-Week High6.89000
icon52-Week Low2.23000
iconAverage Volume1.98M
iconDividend Yield--
iconP/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent. The company has a research collaboration agreement with Stanford University to investigate a novel nucleic acid delivery system developed by Stanford researchers to deliver intracellular RNA or DNA into lymphocytes, including T cells. The company was founded in 2017 and is headquartered in South San Francisco, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Benzinga
10 months ago
Thursday,Allogene Therapeutics Inc(NASDAQ: ALLO) presented the updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in 33 CAR T nave patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) treated with the Alloy manufacturing process material across different&nbs Latest ...
Globe Newswire
10 months ago
Presentation Includes Data on All 33 CAR T-Nave Patients Treated with the Alloy Manufactured Material and Recaps Data on 12 Large B Cell Lymphoma Patients Treated with Phase 2 Dose RegimenResults Indicate an Off-the-Shelf Allogeneic CAR T Can Potentially Deliver Durable Complete Responses Comparable...
Globe Newswire
12 months ago
SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer,today announced it will present updated data from the Phase 1 ALPHA/ALPHA2...
TipRanks Financial Blog
1 year ago
In a report released yesterday, Anthony Butler from EF Hutton maintained a Buy rating on Allogene Therapeutics (ALLO Research Report), with a pri... In a report released yesterday, Anthony Butler from EF Hutton maintained a Buy rating on Allogene Therapeutics (ALLO &#8211...
Globe Newswire
1 year ago
Data Provide Proof-of-Concept for an Allogeneic Anti-CD70 CAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting TherapySingle Infusion of ALLO-316 Demonstrates Promising Anti-Tumor Activity in CD70 Expressing RCC Three of 10 ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$3.47
$0.01
(0.29%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SI-BONE INC
SI-BONE INC
$15.42
$0.12 (0.78 %)
MEIRAGTX HOLDINGS PLC
MEIRAGTX HOLDINGS PLC
$5.09
$0.08 (1.60 %)
IMMATICS NV
IMMATICS NV
$10.21
$-0.05 (-0.49 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$4.52
$-0.28 (-5.83 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
SI-BONE INC
SI-BONE INC
$15.42
$0.12 (0.78 %)
MEIRAGTX HOLDINGS PLC
MEIRAGTX HOLDINGS PLC
$5.09
$0.08 (1.60 %)
IMMATICS NV
IMMATICS NV
$10.21
$-0.05 (-0.49 %)
AUTOLUS THERAPEUTICS PLC
AUTOLUS THERAPEUTICS PLC
$4.52
$-0.28 (-5.83 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00